New Phase 3 analyses show that a single dose of REGEN-COV (casirivimab and imdevimab) provides long-term protection against COVID-19
Dear Investor,Please find attached a press release from our partner Regeneron regarding new follow-up analyses of the 2069 prevention trial that add to the increasing body of evidence supporting the use of Ronapreve to prevent COVID-19:
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
More News: COVID-19 | Pharmaceuticals